ENGLEWOOD, Colo., Feb. 20, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, introduced two new therapy products: the Zynex Pro Hybrid LSO and the Zynex DynaComp Cold Compression.
The Zynex Pro Hybrid LSO is a versatile 3-in-1 spinal orthosis featuring a modular design that adapts seamlessly to individual patient needs. Engineered for optimal comfort and support, this innovative orthosis facilitates a smooth transition from rehabilitation to recovery, allowing for single brace use throughout the entire process.
The Zynex DynaComp Cold Compression is a cutting-edge device that combines cold therapy and compression to accelerate recovery anytime, anywhere. Compact and portable, this innovative device offers on-the-go relief for muscle soreness, swelling, and inflammation, empowering individuals to recover faster and get back to their daily activities with ease.
"We are thrilled to introduce these new products to our customers," Thomas Sandgaard, Founder and CEO, comments. "They will allow our salespeople to compete effectively against other industry leaders in the cold compression and bracing markets. Additionally, they signify our concerted effort to diversify revenue streams, ensuring sustained growth and delivering greater value to our shareholders."
About Zynex
Zynex, founded in 1996, develops, manufactures, markets, and sells medical devices used for pain management and rehabilitation as well as non-invasive fluid, sepsis, and laser-based pulse oximetry monitoring systems for use in hospitals. For additional information, please visit: www.zynex.com.
Investor Relations Contact:
Quinn Callanan, CFA or Brian Prenoveau, CFA
MZ Group – MZ North America
This email address is being protected from spambots. You need JavaScript enabled to view it.
+949 694 9594
Last Trade: | US$2.51 |
Daily Change: | 0.11 4.58 |
Daily Volume: | 244,521 |
Market Cap: | US$79.940M |
June 30, 2025 April 29, 2025 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load